Stock 4162 PHARMAENGINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PharmaEngine, Inc.

Equities

4162

TW0004162003

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
93.3 TWD 0.00% Intraday chart for PharmaEngine, Inc. -0.53% -11.56%
02/05 PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24/04 PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 9,978 8,430 10,207 17,961 15,158 13,405 -
Enterprise Value (EV) 1 9,918 6,594 8,057 17,961 15,158 13,405 13,405
P/E ratio 236 x 14 x 24.7 x 56.3 x 55.2 x 37.6 x 35.5 x
Yield 0.73% 4.32% 3.72% 1.6% 1.42% - -
Capitalization / Revenue 31.8 x 7.98 x 15.6 x 27.4 x 19.7 x 15.9 x 15 x
EV / Revenue 31.8 x 7.98 x 15.6 x 27.4 x 19.7 x 15.9 x 15 x
EV / EBITDA 254 x 10.3 x 27.4 x - - 32 x 28.9 x
EV / FCF 62,87,44,706 x 13,01,55,710 x 1,09,82,158 x - - - -
FCF Yield 0% 0% 0% - - - -
Price to Book 2.86 x 2.12 x 2.67 x 4.64 x 3.92 x 3.45 x -
Nbr of stocks (in thousands) 1,45,667 1,45,597 1,40,596 1,43,687 1,43,679 1,43,678 -
Reference price 2 68.50 57.90 72.60 125.0 105.5 93.30 93.30
Announcement Date 18/03/20 21/03/21 08/03/22 17/03/23 29/02/24 - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 314 1,056 654.8 654.4 767.7 845 894
EBITDA 1 39.32 822.3 373 - - 419 464
EBIT 1 32.61 809.7 362.7 282.7 277.2 374 409
Operating Margin 10.38% 76.68% 55.39% 43.21% 36.11% 44.26% 45.75%
Earnings before Tax (EBT) 1 49.67 752.5 545.4 392.5 338 448 469
Net income 1 42.55 604.3 426 318.8 274.6 361 383
Net margin 13.55% 57.22% 65.06% 48.72% 35.78% 42.72% 42.84%
EPS 2 0.2900 4.140 2.940 2.220 1.910 2.480 2.630
Free Cash Flow 15.87 64.77 929.4 - - - -
FCF margin 5.05% 6.13% 141.94% - - - -
FCF Conversion (EBITDA) 40.36% 7.88% 249.21% - - - -
FCF Conversion (Net income) 37.3% 10.72% 218.16% - - - -
Dividend per Share 0.5000 2.500 2.700 2.000 1.500 - -
Announcement Date 18/03/20 21/03/21 08/03/22 17/03/23 29/02/24 - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 174.1 166.9 154.9 158.5 168.3 - 245.9 187.3 164.5 184 243 254 179 206
EBITDA - - - - - - - - - - - - - -
EBIT 1 116.6 97.22 19.28 49.62 81.09 - 77.52 65.16 67.38 79 114 141 81 97
Operating Margin 66.98% 58.25% 12.45% 31.31% 48.17% - 31.52% 34.79% 40.97% 42.93% 46.91% 55.51% 45.25% 47.09%
Earnings before Tax (EBT) 1 122.1 104.3 101.7 64.36 102.5 - 103.1 60.25 102.7 97 126 149 99 120
Net income 1 97.03 80.67 87.46 53.62 81.38 75.12 80.78 37.37 81.73 78 101 122 81 97
Net margin 55.73% 48.33% 56.47% 33.83% 48.34% - 32.85% 19.95% 49.69% 42.39% 41.56% 48.03% 45.25% 47.09%
EPS 2 0.6800 0.5600 0.6100 0.3700 0.5700 0.5200 0.5600 0.2600 0.5700 0.5400 0.6900 0.8400 0.5600 0.6700
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 06/05/22 03/08/22 04/11/22 17/03/23 04/05/23 04/08/23 06/11/23 29/02/24 02/05/24 - - - - -
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position 59.9 1,836 2,151 - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 15.9 64.8 929 - - - -
ROE (net income / shareholders' equity) 1.19% 16.1% 10.7% - - - -
ROA (Net income/ Total Assets) - 15.4% 10.3% - - - -
Assets 1 - 3,925 4,117 - - - -
Book Value Per Share 2 23.90 27.40 27.20 26.90 26.90 27.00 -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 18/03/20 21/03/21 08/03/22 17/03/23 29/02/24 - -
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for PharmaEngine, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
93.3 TWD
Average target price
106 TWD
Spread / Average Target
+13.61%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PHARMAENGINE, INC. Stock PharmaEngine, Inc.
-11.56% 413M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4162 Stock
  4. Financials PharmaEngine, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW